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Abstract 
Background: Food allergy is the most common cause of anaphylaxis in children. Intramuscular delivery of epineph-
rine auto-injectors (EAI) is the standard of care for the treatment of anaphylaxis. We examined if children and adoles-
cents at risk of anaphylaxis weighing 15–30 kg and >30 kg would receive epinephrine into the intramuscular space 
with the currently available EAI in North America and Europe.
Methods: The distance from skin to muscle (STMD) and skin to bone (STBD) on the mid third anterolateral area of 
the right thigh was measured by ultrasound applying either high pressure (max) or slight pressure (min) in 102 children 
weighing 15–30 kg (group 1) and 100 children and adolescents, weighing more than 30 kg (group 2).
Results: Using a high pressure EAI (HPEAI), Epipen Jr® and Auvi-Q®/Allerject® 0.15 mg, 11/102 (11 %) children in 
group 1 and 38/102 (38 %) using another HPEAI, Jext®, had a STMDmax that showed a risk of intraosseous injection. 
There was a 1 % risk of subcutaneous injection with these devices. There was no risk of intraosseous injection using 
a low pressure EAI (LPEAI), Emerade®. In group 2, the risk of intraosseous injection using a HPEAI was 3 % and no risk 
using a LPEAI. However, the risk of subcutaneous injection using HPEAI was 9 % and using LPEAI was 2 %.
Conclusion: There is a risk of intraosseous injection using HPEAI (Epipen®/Epipen Jr®, Auvi-Q®/Allerject® and 
especially Jext®) in children at risk of anaphylaxis. There was also a risk of subcutaneous injection using the currently 
available HPEAI in children and adolescents.
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Background
Anaphylaxis is a potentially life-threatening reaction that 
can occur from a number of different triggers. In chil-
dren, food allergy is the most common identified cause 
of anaphylaxis [1]. The true prevalence of food allergy 
in children is difficult to define because in most studies 
double blind placebo controlled food challenges are not 
performed to properly confirm the diagnosis [2]. Recent 
estimates suggest a prevalence of approximately 6  % in 
young children and 4  % in adults [1–3]. Currently, the 
prompt administration of intramuscular epinephrine is 
the recommended treatment for anaphylaxis [1, 2]. Out-
side of the hospital setting, epinephrine auto-injectors 
(EAI) are the standard method of administering epi-
nephrine. In North America, the Epipen® [4] and Auvi-
Q® [5] (Allerject® in Canada [6]) are currently the most 
commonly prescribed EAI. Importantly, there are differ-
ent EAI available in Europe with different physical char-
acteristics including pressure required for delivery of the 
medication and needle lengths Table 1.
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The Epipen Jr® and the Auvi-Q®/Allerject® 0.15 mg are 
officially indicated for pediatric patients at risk of ana-
phylaxis who weigh between 15 and 30  kg. In Europe, 
Jext® and Emerade® are available with 0.15 mg per dose. 
For patients who weigh >30  kg, Epipen® and Auvi-Q®/
Allerject® 0.30  mg are indicated. In Europe, Jext and 
Emerade® are available at the same strengths. Emerade® 
is also available at a 0.5 mg dose indicated for treatment 
of adults. The needle lengths and other properties of EAI 
are given in Table 1 [4–6]. There has been concern that 
the EAI may not deliver epinephrine to the intramus-
cular space in both adults and children. In both adults 
and children with and without risk of anaphylaxis, it 
has been identified that a significant number of patients 
may receive epinephrine subcutaneously with the cur-
rently available EAI [7–10]. There has been a contradic-
tory study showing that in children weighing <15 kg, with 
confirmed food allergy, a significant number of children 
may be at risk of receiving the injection into the perios-
teum or bone [11].
In this present study, we sought to evaluate whether 
children and adolescents who are at risk of anaphylaxis 
from food allergy weighing 15–30 kg and >30 kg would 
receive epinephrine into the intramuscular space, the 
bone or subcutaneous space using currently available 
EAI in North America and Europe.
Patients and methods
Patients
All of the parents or legal guardians of each patient pro-
vided written, informed consent before participating in 
this study. The study was approved by the Lawson Health 
Research Institute Ethics Board at the Western University 
in London, Ontario, Canada.
Consecutive patients who were less than 18  years of 
age, with diagnosed food allergy based on an appropriate 
history and positive skin prick testing were recruited into 
the study. They were separated into two groups: those 
who weighed between 15 and 30 kg, Group 1 (n = 102), 
and those who weighed more than 30  kg, Group 2 
(n = 100). Patient characteristics are given in Table 2. All 
of these subjects required a prescription for an EAI for 
food allergy. There were no clinical exclusion criteria. The 
subjects were assessed from July 2012 to June 2014.
Ultrasound estimation distance skin to muscle (STMD) 
and skin to bone (STBD)
An ultrasound of the anterolateral aspect of the right 
mid-thigh, i.e., the recommended location for injecting 
an EAI, was completed on all of the subjects with and 
without pressure using a Sonosite Titan® ultrasound 
machine. The pressure was applied to simulate the pres-
sure required to trigger the HPEAI. The estimated pres-
sure to mimic the pressure applied by the Epipen Jr®, 
Epipen®, Auvi-Q®/Allerject® and Jext® was 8 pounds 
[9]. To mimic the pressure applied to Emerade®, minimal 
pressure was applied.
Four ultrasound measurements were collected on each 
patient: skin-to-muscle depth with low pressure (STM-
Dmin), skin-to-muscle depth with “maximal” pressure 
(STMDmax), skin-to-bone depth with minimal pressure 
(STBDmin) and skin-to-bone depth with “maximal” pres-
sure (STBDmax). Figure 1 shows the principle of measure-
ment. The STMD was measured from the skin surface to 
the inner aspect of the fascia of the vastus lateralis mus-
cle and the bone depth was measured at the outer aspect 
of the periosteum of the femur. The ultrasound measure-
ments were performed by one investigator.
Analysis
The two different weight groups were analyzed sepa-
rately. Recently, Diacono et al. [9] found the needle must 
pass not only through the fascia lata but also the epimy-
sium to deliver a drug into the intramuscular space. If 
part of the orifice stays within the epimysium during 
the injection, epinephrine will spread within the loose 
epimysium tissue. Therefore, the whole needle orifice 
must pass into the muscle for proper administration. The 
Table 1 Characteristics for epinephrine auto-injectors available in Europe and North America
Epinephrine autoinjector (EAI) Epinephrine dose Needle length(mm) Pressure against the thigh
Exposed needle length Distance skin to muscle
Epipen Jr®, Auvi-Q®/Allerject® 0.15 mg 12.7 10.7 Thrust/Pressed firmly
Epipen®Auvi-Q®/Allerject® 0.3 mg 15.2 13.2
Jext® 0.15 mg 0.15 mg 15.7 13.7 Pressed firmly
Jext® 0.3 mg 0.3 mg 15.7 13.7
Emerade® 0.15 mg 0.15 mg 16 14 Slight pressure
Emerade® 0.3 mg 0.3 mg 23 21
Emerade® 0.5 mg 0.5 mg 23 21
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needle lengths used are those given by the manufactur-
ers. The ultrasounds of the mid-anterolateral thigh with 
and without pressure were measured to identify whether 
children with prescribed EAI would be at risk of subcu-
taneous or periosteal/intraosseous delivery of epineph-
rine. The length of the needle orifice was estimated to be 
2 mm. This length was used as our measurement of the 
needle orifice distance for the Epipen Jr® was just over 
2 mm and the Emerade® measurement is 1.7 mm (infor-
mation supplied by the manufacturer Medeca Pharma). 
Therefore, we used the needle length minus 2  mm for 
estimation of the STMD threshold. For estimation of the 
STBD the full length of the needles were used (Table 1 
and Fig. 1).
Outcome variables
We used two primary outcome variables: The proportion 
of children with (1) STBD less than the needle length (2) 
STMD more than the needle length minus 2 mm (Table 1 
and Fig. 1).
Statistics
Differences between groups were calculated using two-
tailed t-test. Correlations were calculated using Spear-
man’s rank correlation coefficient. Also, we estimated the 
proportion of subjects who would likely receive epineph-
rine intramuscularly with the different EAI available in 
North America and Europe.
Results
The patient characteristics for both group 1 (15–30  kg) 
and group 2 (>30 kg) are presented in Table 2. The BMI 
of group 1 was significantly less than that of group 2 
(p < 0.00001) (Table 2). Only 13/202 children had a BMI 
exceeding 25 kg/m2. Therefore, the weight increased with 
age but only a few teenagers were overweight or obese.
In Table  3, further characteristics are analyzed for 
children in Group 1 and differences between those 
with a STBDmax  ≥  12.7  mm and those with a STBD-
max < 12.7 mm, i.e., those without (n = 91) and those with 
(n = 11) a risk of intraosseous injection using a HPEIA 
(Epipen Jr® and Auvi-Q®/Allerject® 0.15  mg). Since 
the age of children varied (interquartile range 48 and 
84 months), and the weight within the range 15–30 kg, all 
other data will vary, most for the STBD, p < 0.0002 and 
BMI, p = 0.0012.
In Table 4, further characteristics of children are ana-
lyzed, i.e., among adolescents in group 2 and differences 
between those with a STBDmax  ≥  15.2  mm and those 
with a STBDmax  <  15.2  mm i.e., those without (n =  97) 
and those with (n  =  3) a risk of intraosseous injection 
using a HPEAI (Epipen® and Auvi-Q®/Allerject® 0.3 mg). 
Since the age of children varied (interquartile range 144 
and 192 months), and the weight between 30 and 89 kg, 
all other data varied, especially for the STBD, p = 0.022.
No child had a risk of intraosseous or subcutaneous 
injection using a LPEAI, Emerade®.
Group 1 (15–30 kg)
In group 1, there were 11/102 subjects with a STBD-
max < 12.7 mm with a risk of intraosseous injection and 
1/102 subject with STMDmax > 10.7 mm (Epipen Jr® and 
Auvi-Q®/Allerject® 0.15  mg) when using Epipen Jr®/
Table 2 Clinical characteristics of children in the study
All subjects had food allergy necessitating the prescription of EAI
a two-tailed t-test












Age (years) 5.7 (2–10) 13.3 (7–18) –
Boys/girls 62/40 60/40 ns
Height (cm) 115.8 (83.8–144.8) 161.7 (121.9–190.5) –
Weight (kg) 21.3 (14.5–29.9) 54.4 (30.4–88.9) –









Fig. 1 Novel approach for measuring the distance from skin to bone 
and skin to muscle. To obtain an intramuscular injection, the STMD 
must be at the most the exposed needle length minus 2 mm (needle 
orifice). There is a risk of intraosseous injection if the STBD is less than 
the full exposed length of the needle (also see Table 1)
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Auvi-Q®/Allerject®, with a risk of subcutaneous injection 
of epinephrine (Table 3).
Furthermore, STBDmax was  <  15.7  mm (Jext®) in 
38/102 children, one child had a STMDmax  >  10.7  mm, 
no child had STBDmin < 16 mm (Emerade®) and no child 
had a STMDmin < 14 mm (Table 5).
In summary, 11/102 children using a HPEAI, Epipen 
Jr® or Auvi-Q®/Allerject®, and 38/102 children, if 
using Jext®, would have the risk of an injection in the 
bone. One of the 102 children would have the risk of a 
subcutaneous injection. No patients were at risk of an 
intraosseous or subcutaneous injection using a LPEAI, 
Emerade® device.
Group 2 (>30 kg)
For the >30 kg group, using Epipen®, Auvi-Q®/Allerject® 
or Jext® there was 3/100 with STBDmax < 15.2 mm indi-
cating a risk of injecting into bone. Furthermore, 9/102 
children had a STMDmax > 13.2 mm and >13.7 mm sug-
gesting a risk of subcutaneous injection (Table 6).
Among the 100 children weighing >30 kg, no child had 
a STBDmin < 23 mm and 2/100 had a STMDmin > 21 mm 
indicating two children would be at risk getting a subcuta-
neous injection with a low pressure EAI such as Emerade®.
In summary, 3/100 children would have a risk of an 
injection into the bone and 9/100 an injection in the 
subcutaneous tissue when using the HPEAI (Epipen®, 
Auvi-Q®/Allerject® or Jext®), whereas 2/100 patients 
had a risk of a subcutaneous injection using a LPEAI 
(Emerade®).
Correlations
The strongest correlation was found between STMD-
max and STMDmin when all children were considered 
(r = 0.96) (Table 7). This correlation was also present in 
both groups, with group 1, r = 0.92, and group 2, r = 0.96 
(p < 0.05). The STBDmax and STBDmin correlated signif-
icantly (p  <  0.05) in all three groups, with a correlation 
coefficient 0.89, 0.56 and 0.88 respectively (Tables  7, 8 
and 9).  
When all children were considered the BMI corre-
lated with STMDmin (r  =  0.60), STMDmax (r  =  0.62), 
STBDmin (r = 0.79) and STBDmax (r = 0.80), all p < 0.05 
(Table  7). Even in the two separate groups, BMI cor-
related with the STMD and STBD measures, but at a 
lower level (Table  8 and 9). In group 1, there was no 
risk of subcutaneous injection for a BMI  <  20  kg/
m2, but there is a risk of intraosseous injection for a 
BMI < 25 kg/m2 using the Epipen Jr® needle length. In 
group 2, there was a risk of subcutaneous injection for 
a BMI > 20 kg/m2 and there was no risk of intraosseous 
injection for BMI > 25 kg/m2 using the Epipen® needle 
length (Figs. 2 and 3). 
Table 3 Characteristics of children 15–30 kg
Distance skin surface to bone with high pressure applied to the ultrasound 
probe (STBDmax). Data on one needle length 12.7 mm are given. Those with 
STBDmax < 12.7 mm. i.e., with a risk of penetrating the femur and those with 
more than 12.7 mm STBDmax. The differences between groups was tested by 
a two-tailed t-test. The inter-quartile ratio (IQR) percentage (%) and standard 
deviations (SD) are given within the brackets
Characteristics Total
(n = 102)







72 (48–84) 72 (48–84) 60 (48–78) 0.019
Males. n (%) 62 (60.4) 54 (59.3) 8 (72.3) 0.074
Weight (kg). mean 
(SD)
21.3 (4.0) 21.4 (3.9) 19.7 (4.2) ns
Height (m). mean 
(SD)
1.16 (0.12) 1.16 (0.12) 1.18 (0.15) ns
BMI (kg/m2). mean 
(SD)
15.8 (2.0) 16.1 (1.9) 14 (1.4) 0.0012
STMDmax (mm). 
mean(SD)
5.8 (1.5) 5.9 (1.5) 4.8 (1.0) 0.025
STMDmin (mm). 
mean (SD)
6.7 (1.7) 6.8 (1.7) 5.5 (1.3) 0.019
STBDmax (mm). mean 
(SD)
16.7 (3.0) 17.3 (2.5) 11.6 (0.9) <0.000001
STBDmin (mm). mean 
(SD)
29.5 (3.9) 30.0 (3.7) 25.4 (2.6) 0.0002
Table 4 Characteristics of children and adolescents > 30 kg
Data on one needle length of 15.2 mm are given. Those with STBDmax < 15.2 mm. 
i.e., at risk of penetrating the femur and those with >15.2 mm STBDmax. The 
differences between groups was tested by a two-tailed t-test. The inter-quartile 











168 (144–192) 168 (144–192) 144 (114–144) 0.07
Males. n (%) 60 (60) 57 (58.8) 3 (100) ns
Weight (kg). 
mean (SD)
54.5 (15.4) 55 (15.3) 36.4 (6.0) 0.012
Height (m). 
mean (SD)
1.62 (0.14) 1.62 (0.14) 1.41 (0.03) 0.041
BMI (kg/m2). 
mean (SD)
20.5 (3.9) 20.5 (3.9) 18.4 (3.9) ns
STMDmax (mm). 
mean (SD)
7.4 (3.8) 7.5 (3.8) 4.6 (0.1) ns
STMDmin (mm). 
mean (SD)
8.4 (4.4) 8.5 (4.5) 5.4 (0.4) ns
STBDmax (mm). 
mean (SD)
25.5 (7.9) 25.8 (7.7) 13.5 (0.5) 0.0075
STBDmin (mm). 
mean (SD)
41.7 (8.9) 42.0 (8.8) 30.1 (4.8) 0.022
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Weight, the variable typically used for dosing epineph-
rine, correlated with the primary variable, BMI (r = 0.85, 
0.25 and 0.82 respectively (Tables 7, 8 and 9), and STBD-
min (r = 0.83, 0.36 and 0.71, respectively).
Characteristics of children at risk of intraosseous injection
In group 1, data on the 11 patients with a STBD-
max < 12.7 mm (EpipenJr® or Auvi-Q®/Allerject®) (Addi-
tional file  1: Table S1a) and the data on the 38 patients 
with a STBDmax  <  15.2  mm (Jext®) (Additional file  1: 
Table S1b) are shown.
Data on three children from group 2 with a STBD-
max < 15.2 mm (Epipen® or Auvi-Q®/Allerject® 0.3 mg), 
i.e., with a risk of intraosseous injection, are shown in 
Additional file 1: Table S1c and data on the nine patients 
with a STMDmax > 15.2 mm (Epipen® or Auvi-Q®/Aller-
ject® 0.3 mg) are shown in Additional file 1: Table S1e.
Compression of subcutaneous tissue, muscle and total 
tissue
Using data from all 202 children, the subcutaneous tissue 
was compressed a mean of 1.1 mm, quartiles 0.4–1.3 mm, 
the muscle mean of 12.7  mm, quartiles 9.4–15.8  mm, 
and the total compression mean of 13.8  mm, quartiles 
10.8–16.8 mm. Thus, the compression originated mainly 
from the muscle compartment, mean of 91.3 %, quartiles 
8.8–96.4 %.
Discussion
This is the first study assessing whether EAIs would 
deliver epinephrine into the intramuscular space in 
children with food allergy who are in the proper weight 
indications for the Epipen® and Auvi-Q®/Allerject®. As 
well, we assess whether EAI only available in Europe 
would be different than the Epipen® and Auvi-Q®/
Allerject®. There is one study assessing STMD without 
pressure in children who were not at risk of anaphylaxis. 
In that study, Stecher [7] found that 12  % of children 
weighing less than 30  kg were at risk of subcutane-
ous injections. We found that more children weighing 
15–30  kg were at risk of intraosseous injection (38  %) 
using a HPEAI not commonly used in North America 
(Jext®).
Importantly, Diacono et al. [9] showed that drug deliv-
ery into the muscle requires that the whole opening of 
the needle bevel must penetrate completely through the 
muscle fascia. This current study is the first using a modi-
fied needle length threshold, which takes into account 
the likelihood that the whole needle bevel should pen-
etrate through the whole muscle fascia in order to deliver 
the drug into the intramuscular space. In this study, we 
used 2  mm less than the total needle length to predict 
whether epinephrine would be delivered intramuscularly. 
However, we used the true exposed needle length to pre-
dict whether the needle would hit the bone. We believe 
this approach would be the most conservative method 
Table 5 Number of  children 15–30 kg at  risk of  subcuta-
neous injection (STMDmax and STMDmin) or periosteal or 
bone injection (STBDmax and STBDmin)
Number of children at risk of getting a subcutaneous injection (STMDmax and 
STMDmin) or injection into the periosteum or bone (STBDmax and STBDmin) for 
the different EAIs. The data are in percentages. For estimation of the penetration 
of the needle into the muscle, STMD, the needle length has been reduced by 











 STBDmax 12.7 – – – 11
 STMDmax 10.7 – 1 – –
Jext®
 STBDmax 15.7 – – – 38
 STMDmax 13.7 – 0 – –
Emerade® 0.15 mg
 STBDmin 16.0 – – 0 –
 STMDmin 14.0 0 – – –
Table 6 Number of children and adolescents >30 kg at risk 
of subcutaneous injection (STMDmax and STMDmin) or peri-
osteal or bone injection (STBDmax and STBDmin)
Number of children at risk of getting a subcutaneous injection (STMDmax and 
STMDmin) or injection into the periosteum or bone (STBDmax and STBDmin) for 
the different EAIs. The data are in percentages. For estimation of the penetration 
of the needle into the muscle, STMD, the needle length has been reduced by 










 STBDmax 15.2 – – – 3
 STMDmax 13.2 – 9 – –
Jext® 0.3 mg
 STBDmax 15.7 – – – 3
 STMDmax 13.7 – 9 – –
Emerade® 0.3 
and 0.5 mg
 STBDmin 23.0 – – 0 –
 STMDmin 21.0 2 – – –
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to predict proper injection into the muscle. As well, the 
strongest correlations were found between STMDmin and 
STMDmax. This observation may be interpreted that the 
pressure on the probe when measuring STMDmax was 
consistent.
This study showed that children weighing 15–30  kg 
would be at 11  % risk of the EIA needle reaching 
the femur with the Epipen Jr® or Auvi-Q®/Aller-
ject® 0.15  mg and 38  % with Jext®. In children weigh-
ing >30  kg, 3  % of children were at risk injection into 
bone with Jext. There was no risk of injection into bone 
using the low pressure EAI, Emerade®. Conversely, 1 % 
of children weighing 15–30 kg and 9 % of those weigh-
ing >30  kg using Epipen Jr®, Auvi-Q®/Allerject® or 
Jext® may receive the epinephrine subcutaneously. No 
children at 15–30 kg and 2 % of those weighing >30 kg 
would have a subcutaneous injection using the low 
pressure EAI, Emerade®. We feel these findings are 
clinically relevant as the EAI have a significant risk of 
delivering the epinephrine into an inappropriate tis-
sue compartment leading to unpredictable serum levels 
of epinephrine. Furthermore, the risk of inappropriate 
tissue delivery varied with the different EAI. The risk 
varied due to different exposed needle lengths and the 
force required to trigger the devices.
Currently, there are no clinical studies proving that 
intramuscular, subcutaneous and interosseous injections 
of epinephrine would lead to different clinical outcomes. 
However, there are small controlled studies showing that 
intramuscular epinephrine likely leads to higher and 
more rapid peak epinephrine levels. There is one study in 
adults [12] and one study in children [13]. The adult study 
has some potential limitations. It was a “prospective, ran-
domized, blinded, placebo-controlled, 6-way crossover 
study of intramuscular versus subcutaneous injection of 
epinephrine in young men.” The study included only 13 
male subjects. The mean BMI, 36.6 ± 4.6 [range 20–64] 
indicated there was very likely increased subcutaneous 
fat layer in some individuals. There appears to be an early 
peak in serum epinephrine levels with a later peak in epi-
nephrine levels at 45  min. The intramuscular injections 
were given with Epipen®. This is a high pressure EAI with 
a relatively short needle (15.2  mm). Thus, we propose 
that, in some subjects, the epinephrine was deposited 
subcutaneously leading to this second peak.
Table 7 Correlations for children >15 kg and <18 years (n = 202)
Variable Height  Weight BMI STMDmin STMDmax STBDmin STBDmax
Weight 0.91
BMI 0.54 0.82
STMDmin 0.17 0.38 0.60
STMDmax 0.19 0.40 0.62 0.96
STBDmin 0.69 0.83 0.79 0.60 0.62
STBDmax 0.60 0.78 0.80 0.62 0.66 0.89
Bold figures indicate significant results at p < 0.05 level. Shadowed values are highlighting the strongest correlations (r > 0.75) that may be of importance
Table 8 Correlations for children 15–30 kg (n = 102)
Height Weight BMI STMDmin STMDmax STBDmin
Weight 0.859
BMI -0.233 0.250
STMDmin -0.136 0.004 0.282
STMDmax -0.110 0.060 0.333 0.924
STBDmin 0.217 0.361 0.305 0.397 0.372
STBDmax 0.141 0.318 0.404 0.481 0.527 0.556
Bold figures indicate significance at p < 0.05 level. Shadowed values are highlighting the strongest correlations (r > 0.75) that may be of importance
Table 9 Correlations for children weighing >30 kg and <18 yrs
Height Weight BMI STMDmin STMDmax STBDmin
Weight 0.762
BMI 0.258 0.815
STMD min -0.124 0.334 0.629
STMD max -0.126 0.340 0.640 0.959
STBD min 0.360 0.713 0.756 0.623 0.655
STBD max 0.279 0.673 0.774 0.619 0.656 0.880
Bold figures indicate significance at the p < 0.05 level. Shadowed values are 
highlighting the strongest correlations (r > 0.75) that may be of importance
Page 7 of 8Dreborg et al. Allergy Asthma Clin Immunol  (2016) 12:11 
In the pediatric study by Simons [13], again the num-
bers are small with only nine children in the group 
receiving epinephrine intramuscularly (by Epipen®). 
There appears to be a secondary peak of serum epineph-
rine in this study as well. Interestingly, a study compar-
ing Epipen® with Auvi-Q®/Allerject® [14] showed these 
products were similar in terms of achieving serum epi-
nephrine levels. However, again there appears to be 
an early peak of epinephrine and a secondary peak at 
30  min. We believe this second peak could have been 
eliminated if all of the subjects had confirmed intramus-
cular injections of epinephrine.
Although there are no human studies assessing clini-
cal effect or epinephrine levels with periosteal or intra-
osseous injections of epinephrine, studies suggest that 
intraosseous injection has similar effects to intravenous 
infusion [15]. Therefore, intraosseous injection with the 
epinephrine from EAIs could lead to dangerously high 
levels in children. There is recent evidence showing that 
intravenous bolus of epinephrine leads to an increased 
risk of cardiovascular side effects compared to intramus-
cular injection [16]. As well, we believe the EAIs would 
penetrate through the bone in children if enough pres-
sure is applied as shown in a case report where an EAI 
needle was inadvertently injected completely through an 
adult’s finger [17]. But in older children, it is possible that 
the EAI needles would not penetrate through the cortical 
bone of the femur.
There are some limitations to this study. Firstly, this 
study was completed at one clinical site and one non-
blinded physician completed all of the ultrasound meas-
urements. The ultrasound measurements were easy to 
perform and a second physician (a radiologist) con-
firmed the measurements in 17 randomly selected chil-
dren showing no significant difference between the two 
investigators. The patients were all from southwestern 
Ontario, Canada. Therefore, this population may not be 
truly representative of other populations. As well, the 
pressure applied, to mimic the pressure applied to a high 
pressure EAI, was estimated to be 8 pounds, but it was 
not measured with each measurement. It would be opti-
mal to complete the measurements with a consistently 
applied pressure with an ultrasound probe with the exact 
surface area of each of the EAI. But this would have been 
technically impossible, as there was no such probe avail-
able at the time of the study.
Again, there are no clinical studies proving that there 
is any benefit of intramuscular epinephrine compared to 
subcutaneous and intravenous epinephrine. Most clinical 
guidelines support intramuscular injection with the EAI 
when required in the treatment of anaphylaxis [18]. The 
findings of this study and others noted above suggest that 
the variability in children’s STMD and STBD supports 
the research and development into EAI with different 
characteristics including varying needle lengths, pressure 
required to trigger injection, and total delivered doses. 
Currently, we believe the only method of confirming 
that an EAI will deliver epinephrine intramuscularly is 
by measuring STMDmin, STMDmax, STBDmin, and STBD-
max with an ultrasound measurement for each individual 
patient. If the STBDmax is less than the clinically impor-
tant needle length, then having the patient or assisting 






















Fig. 2 STMDmax versus BMI. The horizontal lines indicate the length of 
the needle of Epipen Jr® and Epipen® respectively, both minus 2 mm, 
the estimated distance from the point of the needle to the upper 
limit of the orifice. The vertical dotted line indicates the proposed limit 
using Epipen® to avoid subcutaneous injection. The nine subjects at 
risk of subcutaneous injection using Epipen® were all overweight. 
However, children with a BMI < 20 kg/m2 are not at risk getting a 
subcutaneous injection when using the EpiPen® needle 15.2 mm

















Fig. 3 STBDmax versus BMI. The horizontal lines indicate the full length 
of the needle of Epipen Jr® and Epipen® respectively. The vertical dot-
ted lines indicate those at risk of intraosseous injection using Epipen 
Jr® are those with a BMI < 17 kg/m2 and those at risk of intraosseous 
injection using Epipen® are those with a BMI < 25 kg/m2
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adult squeeze the vastus lateralis muscle while giving the 
EAI may prevent the needle from hitting the femur. It is 
important that the EAI does not hit the fingers that are 
squeezing the muscle. If the STMDmax or STMDmin is 
greater than the length of the EAI needle minus 2 mm, 
we believe it is extremely important for patients to always 
carry two EAI and call for medical assistance immedi-
ately if they are required.
Conclusions
In children with food allergy, the HPEAI currently avail-
able in North America will deliver epinephrine to the 
intramuscular space in approximately 9 out of 10 chil-
dren when used properly. In a significant number of 
children weighing 15–30  kg, there is a risk (11–38  %) 
of injecting the epinephrine into the bone with HPEAI 
(Epipen Jr®, Auvi-Q®/Allerject® 0.15  mg and Jext®). 
There is a 9 % risk of a subcutaneous injection in chil-
dren and adolescents weighing more than 30 kg, using 
high pressure EAI (Epipen® or Auvi-Q®/Allerject® 
0.30  mg, Jext®), whereas when using a low pressure 
EAI (Emerade®) we found a 2  % risk of subcutaneous 
injection.
Abbreviations
EAI: epinephrine auto-injector; HPEAI: high pressure EAI; LPEAI: low pressure 
EAI; STMD: skin to muscle distance; STBD: skin to bone distance; STMDmin: skin 
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